| Literature DB >> 24720863 |
Brian Edward Dixon1, Linas Simonaitis, Susan M Perkins, Adam Wright, Blackford Middleton.
Abstract
BACKGROUND: A cloud-based clinical decision support system (CDSS) was implemented to remotely provide evidence-based guideline reminders in support of preventative health. Following implementation, we measured the agreement between preventive care reminders generated by an existing, local CDSS and the new, cloud-based CDSS operating on the same patient visit data.Entities:
Mesh:
Year: 2014 PMID: 24720863 PMCID: PMC4004460 DOI: 10.1186/1472-6947-14-31
Source DB: PubMed Journal: BMC Med Inform Decis Mak ISSN: 1472-6947 Impact factor: 2.796
List of the 11 preventive care reminders provided by CDSC web service
| 1 | [Diabetes] AND [no HgbA1c result within last 6 months] | Diabetic patient is overdue for HgbA1c measurement (recommended every 6 months) |
| • Order HgbA1c now. | ||
| 2 | [Diabetes] AND [last HgbA1C result between 5 and 6 months ago] | Diabetic patient is almost due for HgbA1c measurement (recommended every 6 months) |
| • Order HgbA1c now. | ||
| 3 | [Diabetes] AND [last HgbA1c result between 3 and 5 months ago] AND [greater than 8%] | Last HgbA1c was greater than 8% and over 3 months ago (recommended every 3 months in poorly controlled patient) |
| • Order HgbA1c now. | ||
| 4 | [Diabetes] AND [no established renal disease] AND [no microalbumin result in the last 11 months] | Diabetic patient is due for urine microalbumin/creatinine ratio measurement (recommended yearly) |
| • Order malb/creat ratio now. | ||
| 5 | [Diabetes] AND [chronic renal disease] AND [not ESRD] AND [not taking an ACE-I] AND [not taking an ARB] AND [no contraindication to ACE-I] | Diabetic patient with renal disease, consider starting angiotensin-converting enzyme inhibitor (ACE-I). |
| • Start ACE-I. | ||
| 6 | [Diabetes] AND [chronic renal disease] AND [not ESRD] AND [not taking an ACE-I] AND [not taking an ARB] AND [contraindication exists to ACE-I] AND [no contraindication to ARB] | Diabetic patient with renal disease, contraindications to ACE-I present, consider starting angiotensin-2 receptor antagonist (ARB). |
| • Start ARB. | ||
| 7 | [Diabetes] AND [last eye exam over 11 months ago] | Diabetic patient is due for ophthalmologic exam (recommended yearly) |
| • Document the eye exam. | ||
| • Refer to Ophthalmologist. | ||
| • Refer to Optometrist. | ||
| 8 | [Diabetes] AND [last foot exam over 11 months ago] | Diabetic patient is due for foot exam (recommended yearly) |
| • Document the foot exam. | ||
| • Refer to Podiatrist. | ||
| 9 | No blood pressure within last 12 months | Patient is overdue for blood pressure assessment (recommended yearly) |
| • Document the blood pressure. | ||
| 10 | [CAD] AND [not on any antiplatelet medication] AND [contraindication exists to antiplatelet therapy] | Patient has CAD or equivalent, consider starting anti-platelet therapy, but potential contraindications exist. |
| • Start aspirin. | ||
| • Start clopidogrel. | ||
| 11 | [CAD] AND [not on any antiplatelet medication] AND [no contraindication to antiplatelet therapy] | Patient has CAD or equivalent, recommend starting anti-platelet therapy. |
| • Start aspirin. | ||
| • Start clopidogrel. |
HgbA1c = Hemoglobin A1C. ESRD = End stage renal disease. ACE-I = Angiotensin-converting enzyme inhibitor. ARB = Angiotensin receptor blocker. CAD = Coronary artery disease.
Demographics of study patients compared with overall clinic population
| | ||||
|---|---|---|---|---|
| Age | 52.6 (13.9) | 49.6 (14.9) | ||
| | N | (%) | N | (%) |
| Ethnicity | | | | |
| African-American | 209 | (56.2%) | 8902 | (57.2%) |
| White | 117 | (31.5%) | 4427 | (28.4%) |
| Latino | 3 | (0.8%) | 224 | (1.4%) |
| Other | 12 | (3.2%) | 457 | (2.9%) |
| Unknown | 31 | (8.3%) | 1562 | (10.0%) |
| Gender | | | | |
| Female | 217 | (58.3%) | 9680 | (62.2%) |
| Male | 155 | (41.7%) | 5892 | (37.8%) |
| Primary insurance (first visit) | | | ||
| Wishard advantage | 153 | (41.1%) | 7441 | (47.8%) |
| Medicare | 119 | (32.0%) | 3596 | (23.1%) |
| Medicaid | 47 | (12.6%) | 2322 | (14.9%) |
| Self-pay | 30 | (8.1%) | 878 | (5.6%) |
| Commercial | 23 | (6.2%) | 1331 | (8.5%) |
| Other | 0 | (0%) | 4 | (<1%) |
Raw counts of preventive care reminders delivered by the cloud-based CDSC rules and the locally-crafted CARE rules
| | | ||||
|---|---|---|---|---|---|
| 1. Overdue for A1c | 85 (21%) | 20 (5%) | 7 (72%) | 293 | 0.93 |
| 2. Almost due for A1c | 11 (3%) | 1 (<1%) | 2 (97%) | 391 | 0.99 |
| 3. Recent A1c was over 8 | 4 (1%) | 4 (1%) | 15 (4%) | 382 (94%) | 0.95 |
| 4. Due for microalbumin screening | 110 (27%) | 15 (4%) | 32 (8%) | 248 (61%) | 0.88 |
| 5. Renal disease, consider ACE inhibitor | 12 (3%) | 34 (8%) | 44 (11%) | 315 (78%) | 0.81 |
| 6. Renal disease, contraindications for ACE inhibitor, consider ARB | 1 (<1%) | 0 (0%) | 3 (1%) | 401 (99%) | 0.99 |
| 7. Due for eye exam | 204 (50%) | 12 (3%) | 8 (2%) | 181 (45%) | 0.95 |
| 8. Due for foot exam | 140 (35%) | 27 (7%) | 7 (2%) | 231 (57%) | 0.92 |
| 9. Due for blood pressure | 84 (21%) | 127 (31%) | 9 (2%) | 185 (46%) | 0.66 |
| 10. CAD, consider anti-platelet | 35 (9%) | 8 (2%) | 72 (18%) | 290 (72%) | 0.80 |
| 11. CAD, consider anti-platelet, but contraindications exist | 2 (<1%) | 29 (7%) | 2 (<1%) | 372 (92%) | 0.92 |
P0 = observed agreement, the proportion of times both CDSC rule and CARE rule agreed. A1C = Hemoglobin A1C. ACE Inhibitor = Angiotensin converting enzyme inhibitor. ARB = Angiotensin receptor blocker. CAD = Coronary artery disease.
Unadjusted kappa statistic, as well as prevalence-adjusted bias-adjusted kappa
| 1. Overdue for A1c | 0.82 | -0.03 | -0.51 | 0.87 | 0.82 – 0.91 |
| 2. Almost due for A1c | 0.88 | 0.00 | -0.94 | 0.99 | 0.97 – 1.00 |
| 3. Recent A1c was over 8 | 0.28 | 0.03 | -0.93 | 0.91 | 0.86 – 0.95 |
| 4. Due for microalbumin screening | 0.74 | 0.04 | -0.34 | 0.77 | 0.70 – 0.83 |
| 5. Renal Disease, consider ACE inhibitor | 0.13 | 0.02 | -0.75 | 0.61 | 0.54 – 0.69 |
| 6. Renal disease, contraindications for ACE inhibitor, consider ARB | 0.40 | 0.01 | -0.99 | 0.99 | 0.97 – 1.00 |
| 7. Due for eye exam | 0.90 | -0.01 | 0.06 | 0.90 | 0.86 – 0.94 |
| 8. Due for foot exam | 0.82 | -0.05 | -0.22 | 0.83 | 0.78 – 0.89 |
| 9. Due for blood pressure | 0.34 | -0.29 | -0.25 | 0.33 | 0.24 – 0.42 |
| 10. CAD, consider anti-platelet | 0.37 | 0.16 | -0.63 | 0.60 | 0.53 – 0.68 |
| 11. CAD, consider anti-platelet, but contraindications exist | 0.10 | -0.07 | -0.91 | 0.85 | 0.79 – 0.90 |
K = Kappa statistic. BI = Bias Index. PI = Prevalence Index. PABAK = Prevalence-adjusted Bias-adjusted Kappa. CI = Confidence Interval. A1C = Hemoglobin A1C. ACE Inhibitor = Angiotensin converting enzyme inhibitor. ARB = Angiotensin receptor blocker. CAD = Coronary artery disease.